BTIG downgraded Mersana Therapeutics to Neutral from Buy without a price target after the company terminated upifitamab rilsodotin development after the Uplift trial results. The analyst downgrade the shares pending additional data from Mersana’s two other assets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRSN:
- Mersana Faces Catastrophe After Test Flub
- Mersana Therapeutics downgraded to Neutral from Buy at Guggenheim
- Mersana Therapeutics downgraded to Neutral from Outperform at Wedbush
- Mersana Therapeutics downgraded to Hold from Buy at Truist
- Mersana (NASDAQ:MRSN) Nosedives after Ovarian Cancer Trial Disappoints